BioPharmX
Biotechnology ResearchCalifornia, United States2-10 Employees
BioPharmX is a biotechnology company based in San Jose, California. It concentrates on developing prescription dermatology products for chronic skin conditions that are not adequately addressed by existing therapies. The company utilizes a proprietary HyantX delivery system to support dermatology applications. Its development pipeline includes BPX-04 for papulopustular rosacea and BPX-01 for acne vulgaris. The firm operates as a small biotechnology company within the dermatology segment of the industry and is listed on the NYSE American under the ticker BPMX. In 2019 BioPharmX announced the appointment of Steven M. Bosacki as Chief Operating Officer, a leadership move noted in company events.